Clinical trials: Graft Survival
Acute Graft Rejection, Chronic Allograft Nephropathy
Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
After alemtuzumab induction, followed with kidney transplantation, patients will be randomly assigned to receive either tacrolimus or cyclosporine microemulsion in combination with mycophenolates.
- Conditions
- Acute Graft Rejection, Chronic Allograft Nephropathy, Polyomavirus-related Transplant Nephropathy
- Trial name
- RSCS-Campath (NCT01346397)
- Testing
- cyclosporine or tacrolimus
- Where
- Russia
- Volunteers
- 170 people
- Sponsor
- Russian Academy of Medical Sciences
Liver Transplantation, Low-weight Children
Outcomes of Liver Transplantation in Low Weight Children After Reducing the Lateral Segment of a Living Donor, Adapting the Shape and Size of the Graft to the Needs of the Recipient
The shortage of organs has always been a problem in pediatric liver transplants due to the lack of donors with an adequate size.
- Conditions
- Liver Transplantation, Low-weight Children, Hyper-reduced Liver Grafts
- Trial name
- NCT03594864
- Testing
- Liver transplantation with hyper-reduced grafts
- Where
- Argentina
- Volunteers
- 58 people
- Sponsor
- Hospital Italiano de Buenos Aires
Corneal Neovascularization, Corneal Graft Failure
A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival
The goal of this study is to investigate whether using bevacizumab (Avastin®) is both safe and effective at decreasing the likelihood of a high-risk corneal graft rejection.
- Trial name
- NCT01996826
- Testing
- Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Reza Dana, MD
Renal Transplantation
A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac
This is a retrospective analysis of two different cohorts of patients that has undergone renal transplantation. This is a matched pair analysis of 100 patients treated with generic tacrolimus that will be compared with 100…
- Trial name
- GenTac (NCT02587052)
- Testing
- Generic tacrolimus, Prograf
- Where
- Sweden
- Volunteers
- 186 people
- Sponsor
- Vastra Gotaland Region
Androgenetic Alopecia, Cicatricial Alopecia
Evidence-Based Integrated Protocol to Maximize Hair Follicle Survival in Follicular Unit Extraction (FUE)
Follicular unit extraction (FUE) is a widely used surgical technique for hair restoration, yet hair follicle survival rates vary depending on surgical instrumentation, graft handling, and perioperative care.
- Trial name
- NCT07850011
- Testing
- Integrated Evidence-Based FUE Protocol, Standard FUE Practice
- Volunteers
- 30 people
- Sponsor
- Assiut University
Wound; Head, Multiple, Wound; Head, Scalp
Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
This study will evaluate the use of free autologous dermal fat grafting (also called free dermal fat autografting) to treat complex craniofacial wounds that have failed standard treatment and to understand how well these grafts…
- Conditions
- Wound; Head, Multiple, Wound; Head, Scalp, Wound; Head, Wound Infection
- Trial name
- FTFDT3 (NCT03872544)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dufresne, Craig, MD, PC
Myelofibrosis
Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France
The investigators would like to conduct a retrospective study in five centers in France in the goal to evaluate the survival of patients receiving allogeneic hematopoietic stem cell transplantation for myelofibrosis.
- Trial name
- SYMFASCT (NCT04282421)
- Volunteers
- 58 people
- Sponsor
- Central Hospital, Nancy, France
Ischemia-Reperfusion Injury, Kidney Diseases
Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8.
- Trial name
- NCT00248040
- Testing
- Reparixin continuous infusion, reparixin intermittent infusion
- Where
- 9 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Dompé Farmaceutici S.p.A